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http:WHAT THIS PAPER ADDS
The C3 Gore Excluder stent-graft has a redesigned deployment mechanism that allows for multiple reposi-
tioning, both for level and orientation, prior to ﬁnal deployment. One of the modules of the GREAT registry was
designed to monitor the “real-world” performance of the C3 Gore Excluder. The present report presents the
combined experience of 13 European centers with the use of the C3 Gore Excluder on 400 patients. The early
results show that repositioning before ﬁnal stent-graft deployment is feasible, safe, and useful in “real-life”
conditions, contributing to precise proximal deployment. Longer follow-up will show whether more precise
proximal deployment results in better EVAR durability and reduced need for reintervention.Objectives: The European C3 module of the Global Registry for Endovascular Aortic Treatment (GREAT) provides
“real-world” outcomes for the new C3 Gore Excluder stent-graft, and evaluates the new deployment mechanism.
This report presents the 1-year results from 400 patients enrolled in this registry.
Methods: Between August 2010 and December 2012, 400 patients (86.8% male, mean age 73.9  7.8 years)
from 13 European sites were enrolled in this registry. Patient demographics, treatment indication, case planning,
operative details including repositioning and technical results, and clinical outcome were analyzed.
Results: Technical success was achieved in 396/400 (99%) patients. Two patients needed intraoperative open
conversion, one for iliac rupture, the second because the stent-graft was pulled down during a cross-over
catheterization in an angulated anatomy. Two patients required an unplanned chimney renal stent to treat partial
coverage of the left renal artery because of upward displacement of the stent-graft. Graft repositioning occurred
in 192/399 (48.1%) patients, most frequently for level readjustment with regard to the renal arteries, and less
commonly for contralateral gate reorientation. Final intended position of the stent-graft below the renal arteries
was achieved in 96.2% of patients. Thirty-day mortality was two (0.5%) patients. Early reintervention (30 days)
was required in two (0.5%) patients. Mean follow-up duration was 15.9  8.8 months (range 0e37 months). Late
reintervention (>30 days) was required in 26 (6.5%) patients. Estimated freedom from reintervention at 1 year
was 95.2% (95% CI 92.3e97%), and at 2 years 91.5% (95% CI 86.8e94.5%). Estimated patient survival at 1 year
was 96% (95% CI 93.3e97.6%) and at 2 years 90.6% (95% CI 85.6e93.9%).rresponding author. E.L.G. Verhoeven, Klinikum Nürnberg, Breslauer
201, 90471 Nürnberg, Germany.
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132 E.L.G. Verhoeven et al.Conclusions: Early real-world experience shows that the new C3 delivery system offers advantages in terms of
device repositioning resulting in high deployment accuracy. Longer follow-up is required to conﬁrm that this high
deployment accuracy results in improved long-term durability.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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deploymentINTRODUCTION
Endovascular aneurysm repair (EVAR) is an accepted alter-
native to open surgery for the treatment of suitable
infrarenal abdominal aortic aneurysms (AAA) with short-
term advantages and comparable longer-term out-
comes.1,2 Successful EVAR is highly dependent on suitable
proximal anatomy. Hostile infrarenal neck anatomy (short
length, severe angulation, and circular thrombus/calciﬁca-
tion) have been associated with poorer EVAR short- and
long-term outcomes.3,4
Since the introduction of EVAR two decades ago, stent-
graft manufacturers have been trying to evolve the stent-
graft technology aiming to broaden anatomic eligibility,
and improve operative and long-term outcomes.5,6 The
manufacturer of the Excluder stent-graft, W.L. Gore (W.L.
Gore & Associates, Flagstaff, AZ, USA) has made a number
of design improvements to the existing and well-
documented Excluder stent-graft, with the most notable
involving the modiﬁcation of the ePTFE fabric, to reduce
porosity and ﬂuid transmigration. The redesigned Gore
Excluder stent-graft performs well, with proven efﬁcacy and
durability.7e9 Established advantages of the Excluder
include ﬂexibility and good adaptation of the graft limbs to
complex angulated iliac anatomies.10 Proximal deployment
control however seems somewhat inferior to other stent-
graft systems.11 Therefore, the proximal deployment sys-
tem was completely redesigned to allow for repositioning
prior to ﬁnal deployment, with the aim to improve the
proximal deployment accuracy and aid cannulation of the
contralateral gate.
To investigate the real-world performance of the new C3
Excluder stent-graft, a registry was set up by the manu-
facturer. The European C3 module is part of W.L. Gore’s
Global Registry for Endovascular Aortic Treatment (GREAT).
Herein, are reported the 1-year results of the 400 patients
enrolled in the European multicenter, post-market, pro-
spective registry.
PATIENTS AND METHODS
GREAT and patient population in the C3 module
GREAT was set up in an attempt to identify global trends in
device usage and actively track long-term device perfor-
mance and patient outcomes. GREAT aims to collect data as
a potential mechanism to provide worldwide exposure on
Gore product effectiveness. Moreover, GREAT intends to
become a global clinical research organization for investi-
gational product evaluations. One of the modules of GREAT
collects and analyzes data regarding the C3 delivery system
in Europe.Between August 2010 and December 2012, consecutive
patients treated with the C3 Excluder from 13 European
sites were enrolled in the C3 European module of GREAT. To
reﬂect real-world performance of the device, patients
treated outside the instructions for use (IFU) were also
included in the Registry. Participants were considered to be
outside IFU according to the reporting standards if12
1. the proximal neck length was less than 1.5 cm. This was
deﬁned as the distance between the lowest renal artery
and the origin of the aneurysmal dilation of the aorta,
and/or
2. the infrarenal neck angle was greater than 60 degrees.
Neck angle was deﬁned as the angle between the
longitudinal axis of AAA neck and the longitudinal axis of
the AAA sac.
All included patients provided written informed consent
for their participation in the study. The trial was conducted
according to the Declaration of Helsinki and the Interna-
tional Conference on Harmonization (ICH) and Good Clinical
Practice (GCP) guidelines, and approved by the ethical
committee of each participating institution.Stent-graft design
The C3 Gore Excluder stent-graft is a third-generation
modern device featuring an original design with a ﬂexible,
catheter-mounted introduction, and active infrarenal
attachment with barbs. The deployment mechanism has
been modiﬁed into a three-step sequence, which enables
positioning of the stent-graft up to three times prior to ﬁnal
release from the delivery catheter.13 In the ﬁrst step, the
body and contralateral limb are opened. A constraining loop
around the body of the graft enables recapturing and
repositioning of the stent-graft both for level and orienta-
tion. At the second step the constraining wire and loop are
removed (after conﬁrmation of correct proximal position).
The ipsilateral limb is deployed as a separate third step.Procedure
All patients had a preoperative stent-graft plan featuring
length and diameter of the chosen stent-grafts according to
their aortic and iliac dimensions. An oversize of at least
2 mm compared to the aortic inner diameter (10e21%
oversizing) and 1 mm compared to the iliac inner diameter
(7e25% oversizing) is recommended per IFU. The procedure
was performed under local, regional, or general anesthesia
and via percutaneous or surgical-cut down access according
to operator’s preference. Heparin and antibiotic were
Table 1. Patient demographics and risk factors.
Patient characteristics and risk factors
Gender n ¼ 400
Male 86.8%
Female 13.3%
Age (yrs)
Mean (SD) 73.9 (7.8)
Risk factors
Hypertension 76.2%
Hypercholesterolemia 59.2%
Tobacco use 39.9%
Coronary artery disease 39.0%
Coronary artery bypass graft 13.3%
Congestive heart failure 7.8%
Peripheral arterial disease 22.6%
Chronic obstructive pulmonary disease 16.7%
Diabetes mellitus 13.4%
Renal insufﬁciency 11.8%
Renal dialysis 1.0%
Stroke 8.3%
Carotid disease 6.4%
ASA classiﬁcation
I 1.8%
II 34.8%
III 58.3%
IV 5.1%
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regimen. The need for and details of level and/or orienta-
tion repositioning were documented for every procedure.
Adjunctive procedures (e.g., proximal cuff extender im-
plantation) needed were also documented. A completion
angiogram was routinely performed to document ﬁnal po-
sition of the stent-graft and to exclude endoleak.
Technical success was deﬁned as successful deployment
of the stent-graft with no type I/III endoleak, unintentional
coverage of visceral aortic branches or internal iliac arteries
at the end of the procedure, and with successful removal of
the delivery system. Primary conversion was considered a
technical failure.
Follow-up
Follow up was accomplished according to the protocol of
each institution. No speciﬁc imaging tests at particular time
points were required. Serious adverse events either related
or unrelated to the stent-graft were recorded. Serious
endoleak, stent-graft migration, and reintervention required
during follow-up were also recorded. The time and cause of
death were also documented.
Data collection and processing
Collected data were recorded on a web-based electronic
report form (iMedidata, Medidata Worldwide Solutions,
Inc., New York, NY, USA) to ensure reliability, and secure
authentication and traceability. Data management was
performed by the Gore Clinical Research Department (W.L.
Gore & Associates). All collected data were reviewed and if
missing or inconsistent data were detected, relevant queries
were posed to the investigators for resolution.
Monitoring visits were performed at each enrollment site
to verify necessary study documents, including signed
informed consent for each patient. Consistency between
electronically imported data and source documents was
also examined.
Statistical analysis
Statistical analysis was performed by the Gore Clinical
Research Department. All variables are reported descrip-
tively. Categorical variables are expressed as percentage.
Continuous variables are presented as mean  standard
deviation. Cumulative patient survival and freedom from
reintervention during follow-up were subjected to Kaplane
Meier analysis. All data were analyzed using statistical SAS
software, version 9.2 of the SAS System for Windows
(Copyright 2002e2008 by SAS Institute INC., Cary, NC, USA).
RESULTS
Baseline data
Between August 2010 and December 2012, 400 consecutive
patients (86.8% male, mean age 73.9  7.8 years) from 13
European sites were enrolled in the C3 European module of
GREAT. The patient demographics and risk factors have
already been presented in a previous paper and aresummarized in Table 1.14 Results from 74 of these patients
have also been included in a previously published report
originating from one of the participating centers.15
Elective AAA was the most common indication for
treatment (377/400, 94.3%), followed by common iliac ar-
tery aneurysm (13/400, 3.2%), ruptured AAA (6/400, 1.5%),
aortocaval ﬁstula (2/400, 0.5%), symptomatic 8-cm internal
iliac artery aneurysm (1/400, 0.25%), and aorto-bi-iliac
aneurysm (1/400, 0.25%).
In 393/400 (98.2%) patients, the C3 Excluder implanta-
tion was performed as a primary procedure. In the
remaining cases, the C3 Excluder was used to repair aneu-
rysms after prior open (3/400, 0.8%) or endovascular (4/
400, 1%) aortic procedures.
The mean maximum aneurysm diameter was
59.9  11.4 mm (range 24e110 mm). The proximal aortic
neck had a mean length of 28.0  14 mm (range 2e95 mm)
and a mean angulation of 29.1  24.4 (range 0e100). Six
patients had a neck length shorter than 10 mm. Four of
them had a neck length of 9 mm, one of 3 mm, and one of
2 mm. The last two patients were both treated with bilat-
eral renal chimney grafts. Sixty-eight (17%) patients were
treated outside one or more IFUs for the C3 Excluder stent-
graft.14Operative data
The procedures were performed under general anesthesia
in 90.5%, regional anesthesia in 9%, and local anesthesia in
0.5% of cases. Access was obtained via surgical cut-down in
288/400 (72%), percutaneously in 70/400 (17.5%), and with
a combination of both techniques (1 groin open, 1 groin
134 E.L.G. Verhoeven et al.percutaneous) in 42/400 (10.5%) of patients. A surgical
conduit for access was needed in two (0.5%) cases. Median
procedure duration was 120 minutes (range 50e667
minutes).
Intraoperative stent-graft repositioning and need for
proximal cuff extender
Two hundred and seventy-nine repositioning maneuvers
were performed in 192/399 (48.1%) patients. The most
frequently reported (69%) reason for repositioning was
level readjustment with regard to the renal arteries, fol-
lowed by contralateral gate reorientation (17%). Other less
frequently reported reasons for repositioning (14%) mainly
included intentional initial deployment above the renal ar-
teries to facilitate catheterization of the contralateral gate
within a previous stent-graft, and intentional twisted limb
positioning after successful catheterization of the contra-
lateral gate. The mean number of repositionings performed
per case was 1.5  0.7. One repositioning maneuver was
performed in 123/192 (64%), two in 54/192 (28.1%), three
in 12/192 (6.3%), and four in 3/192 (1.6%) patients. The
exact ﬁnal position, according to the implanting physician,
was achieved in 96.2% of patients, and within 5 mm of the
intended position in an additional 1.5% of patients. Table 2
summarizes stent-graft repositioning data.
Adjunctive proximal cuff extender implantation was
required in 21/398 (5.3%) patients. In 19 (4.8%) patients,
implantation of the proximal cuff was unplanned. The main
reason for unplanned proximal cuff use was treatment of
type I endoleak (n ¼ 9), increase of sealing zone (n ¼ 5),
increase of radial force (n ¼ 3), and extension of landing
zone (n ¼ 2).
Perioperative outcome
Technical success was achieved in 396/400 (99%) patients.
Two patients needed intraoperative open conversion, one
for iliac rupture, the second because the stent-graft was
pulled down during a cross-over catheterization in an
angulated anatomy. Two patients required an unplanned
chimney renal stent to treat partial coverage of the left
renal artery due to stent-graft upward displacement. In one
patient the stent-graft was displaced upwards due to
excessive upward readjustment of the ipsilateral limb to
preserve the hypogastric artery. In the second patient, theTable 2. Summary of proximal trunk repositioning data.
Number of patients reporting trunk
repositioning
192/399
(48.1%)
Reasons for repositioning
Positioning closer to renal arteries 67%
Contralateral gate positioning 19%
Other 14%
Mean (SD) repositions per case 1.5 (0.7)
Number of repositions per case
1 123 (64%)
2 54 (28.1%)
3 12 (6.3%)
4 3 (1.6%)stent-graft migrated proximally during advancement of an
iliac limb. There were no intraoperative deaths.
The thirty-day mortality was 2 (0.5%) patients. One pa-
tient died of respiratory failure, and one due to cardiac
failure. The intensive care unit (ICU) admission rate was 96/
400 (24%). Median hospital stay including a preoperative
admission day was 5 days (range 1e53 days). Peri-operative
procedure-related serious adverse events were noticed in
29/400 (7.3%) patients (Table 3). There was one (0.3%)
device-related serious adverse event: an ipsilateral limb-
graft appeared to be twisted after extensive reorientation
during the procedure for contralateral gate cannulation,
which resulted in an asymptomatic stenosis. The limb was
stented preventively after 2 months. Early (30 days)
reintervention was required in two (0.5%) patients. Both
patients had a signiﬁcant stenosis of an iliac limb-graft due
to extreme kinking of the common iliac artery and under-
went prophylactic stent relining. No stent-graft migration
was observed within 30 days of the procedure.Follow-up
Mean follow-up duration was 15.9  8.8 months (range 0e
37). Twenty-eight patients died during follow-up: 26 due to
aneurysm unrelated causes and two due to unknown cause.
Cumulative patient survival as estimated by KaplaneMeier
was 96% (95% CI 93.3e97.6%) and 90.6% (95% CI 85.6e
93.9%) at 1 and 2 years, respectively (Fig. 1). No patients
required conversion to open repair during follow-up. No
stent-graft migration was noticed in any patient during
follow-up.
Aneurysm sac shrinkage (>5 mm) during follow-up was
noticed in 36% of the patients, stable aneurysm diameter
(5 to þ5 mm) was seen in 59%, and aneurysm sac growth
in 5%. Overall, the mean aneurysm diameter decreased
from 59.9  11.4 mm to 53.7  10.3 mm (p < .001).
Late reintervention (>30 days) was performed in 26
cases. Sixteen reinterventions were performed for endo-
leak. These included 12 type II endoleaks treated with coil/
onyx embolization, two type Ia endoleaks (both in outside
IFU necks) treated with proximal cuff implantation, and two
type Ib endoleaks treated with limb-graft extension. Two of
six chimney stents needed reintervention, one for stenosis
treated with stent extension and one for acute occlusion
treated with recanalization and stenting. Three iliac occlu-
sions were treated, two within the iliac limb-graft, and oneTable 3. Summary of perioperative serious adverse events.
Number of subjects enrolled 400
Any serious event 29 (7.3%)
Lower limb ischemia 3 (0.8%)
Pulmonary complications 4 (1%)
Pulmonary embolism 2 (0.5%)
Cardiac complications 2 (0.5%)
Device related adverse events 1 (0.3%)
Ischemic stroke 1 (0.3%)
Renal complications 6 (1.5%)
Post procedural hemorrhage 2 (0.5%)
Other 8 (2%)
Figure 2. KaplaneMeier estimate of freedom from reinterventions
during follow-up. The grey area above and below the centerline
represents the 95% CI.
Figure 1. KaplaneMeier estimate of cumulative patient survival
during follow-up. The grey area above and below the centerline
represents the 95% CI.
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limb-graft stenoses (1 due to twisting, 1 due to kinking)
were treated with preventive stenting. One reintervention
was carried out to treat a femoral artery pseudoaneurysm.
One patient with an inadequate proximal seal due to neck
dilatation, but without clear proximal endoleak, was
admitted with a rupture after being involved in a road
trafﬁc accident as a passenger. He was treated with a cuff in
the acute situation, and later with another cuff with three
chimneys, and is still alive. In the last patient, the stent-graft
main body collapsed in an angulated neck. This was treated
with a Palmaz stent. Estimated freedom from reintervention
at 1 year was 95.2% (95% CI 92.3e97%), and at 2 years
91.5% (95% CI 86.8e94.5%) (Fig. 2).
DISCUSSION
Since the introduction of EVAR, stent-graft manufacturers
have been improving device technology with the aim of
improving long-term durability, but also to expand anatomic
eligibility. To evaluate new devices, randomized controlled
trials, although providing the highest scientiﬁc level of evi-
dence, do present disadvantages including slow patient
recruitment, prolonged study period, and often poor
generalizability and clinical relevance of the ﬁndings. High-
volume observational studies in the form of registries may
better reﬂect the real-world performance of new devices.16
This is the reason why W.L. Gore have sponsored a registry
with the new C3 Gore Excluder stent-graft in Europe.
Early outcomes of the ﬁrst 400 patients of the European
C3 module of GREAT reveal excellent real-world perfor-
mance of the new C3 Gore Excluder stent-graft, with a very
low surgical mortality and high technical success. Proximal
trunk repositioning was performed in almost half of thepatients, mostly for level readjustment in relation to the
renal arteries. This resulted in a high rate (96.2%) of accu-
rate proximal deployment of the stent-graft and low use
(4.8%) of unplanned proximal cuff-extenders, which was
lower than older EVAR series.17,18 Long-term follow-up will
show whether more accurate proximal positioning also
leads to better long-term results.
The new C3 deployment mechanism provides several
options for readjustment of the Excluder stent-graft, which
can be used in different scenarios.13,19 The ability to repo-
sition the device for proximal level enables accurate
deployment in relation to the renal arteries as shown
above. This proves beneﬁcial both for inexperienced users
(second and third chance for accurate deployment), and for
experienced users in cases with challenging neck anatomy.
The option to adjust the orientation of the contralateral
gate could be used to facilitate catheterization. The ipsi-
lateral limb deployment is a separate step, which may allow
the limb to be pushed upwards during slow, controlled
deployment. This could avoid inadvertent overstenting of
the hypogastric artery.19 This maneuver is not described in
the IFU and should be performed with caution.
The IFU advises a maximum of two repositionings, but
the registry data show that repositioning was safely
repeated up to four times. No device-related failure, aortic
tear, dissection, or distal embolization was recorded in 192
patients with 279 repositioning maneuvers. Nevertheless,
risks associated with excessive repositioning are inherent.
Reconstraining the stent-graft and upward level reposi-
tioning may be difﬁcult in narrow, long, and/or angulated
neck anatomy due to increased friction. In this type of
adverse anatomy, the stent-graft should be deployed
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somewhat higher, with the option to pull it down if needed.
Excessive rotational reorientation may occasionally cause
twisting of the ipsilateral limb. When reorienting the graft
to facilitate limb catheterization, later ipsilateral limb
deployment should be done slowly under continued ﬂuo-
roscopy. This enables de-rotating the limb to avoid twisting.
Finally, excessive upward readjustment of the ipsilateral
limb, aiming to avoid hypogastric artery overstenting, could
result in upward migration of the proximal trunk, as expe-
rienced in one case.19 Attention should therefore be paid to
ensure that the proximal edge of the stent-graft remains in
position during pushing-up of the ipsilateral limb to readjust
its length. Alternatively, an inﬂated balloon within the body
of the stent-graft inserted from the contralateral side would
probably prevent upward migration during readjustment of
the ipsilateral limb.
Seventeen percent of the patients were treated outside
the IFU for the C3 Excluder. Delivery; positioning and
deployment of the stent-graft were not affected. Technical
success and stent-graft deployment accuracy remained high
as previously published, but two type Ia endoleaks occurred
during early follow-up, requiring reintervention.14 There-
fore, it should not be advocated to treat shorter necks,
especially if other options such as fenestrated grafting are
possible.
During follow-up, a stent-graft body collapse occurred 4
months after implantation causing acute onset of claudi-
cation. This occurred in a patient with a long angulated
neck. At the end of the initial procedure, the C3 Excluder
clearly lacked perfect apposition, despite repeated
ballooning. The graft collapsed into a crescent shape with a
very small lumen. Treatment was successful with implan-
tation of a Palmaz stent. A similar problem has incidentally
been reported with the old Excluder stent-graft.20
Late reintervention (>30 days) was required in 26 (6.5%)
patients during follow-up, with estimated freedom from
reintervention at 1 year of 95.2% (95% CI 92.3e97%). These
reintervention rates are relatively high, but comparable
with previously published registries of other contemporary
stent-grafts.21 The most common reason for reintervention
was endoleak repair. The high rate of type II endoleak repair
(46.2% of all reinterventions) should be taken into account
when looking at the overall reintervention rates. This
probably reﬂects an overall trend towards more aggressive
treatment of type II endoleaks. Reintervention for limb-
graft occlusion was very low (0.5%), which conﬁrms the
excellent performance of Excluder limb-grafts, even in
difﬁcult iliac anatomies.22
Recently, the early results of the ENGAGE registry were
published, showing promising real-world performance of
the Endurant stent-graft (Medtronic Endovascular, Santa
Rosa, CA, USA) in the short term. Early results of the C3
Excluder are comparable to the results of the ENGAGE
registry in terms of initial technical success (both 99.0%),
30-day mortality (0.5% GREAT vs. 1.3% ENGAGE), and esti-
mated patient survival at 1 year (96% GREAT vs. 91.6%
ENGAGE). Estimated freedom from reintervention at 1 yearwas also similar between the two registries (95.2% GREAT
vs. 95.1% ENGAGE), although different trends in the leading
reasons for reintervention were shown (Type II endoleaks
for C3 Excluder, iliac limb-graft occlusions for ENGAGE).
Limitations of the present study should be acknowl-
edged. Data, although prospectively collected, were retro-
spectively analyzed. Follow-up schemes and reintervention
protocols differed between centers. Selection bias is also
inherent due to the observational design of the study.
Finally, follow-up time in this registry is still limited, pre-
cluding ﬁrm conclusions on the impact of the new C3
deployment mechanism on long-term durability.
CONCLUSIONS
Real-world performance as reﬂected by the European C3
module of GREAT indicates that the new C3 Excluder stent-
graft offers excellent early and short-term outcome. Graft
repositioning was used in almost 50% of cases, with excel-
lent results in terms of accurate proximal position. The
reorientation option was also used with success, but less
frequently. Longer follow-up is needed to conﬁrm these
results, and to prove that more accurate proximal position
of the stent-graft results in better EVAR durability and
reduced need for reintervention.
CONFLICT OF INTEREST
Eric L.G. Verhoeven has received educational grants and is a
consultant for Cook Inc., W.L. Gore & Associates, Siemens
and Atrium-Maquet. Hence Verhagen is a consultant for
W.L. Gore & Associates and Medtronic. Thomas Larzon has
received educational grants from W.L. Gore & Associates.
Dittmar Böckler has received speaker fees and is a consul-
tant for W.L. Gore & Associates.
FUNDING
GREAT was funded by W.L. Gore & Associates.REFERENCES
1 De Bruin JL, Baas AF, Buth J, Prinssen M, Verhoeven EL,
Cuypers PW, et al. Long-term outcome of open or endovascular
repair of abdominal aortic aneurysm. N Engl J Med 2010;362:
1881e9.
2 Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van
Sambeek MR, Balm R, et al. A randomized trial comparing
conventional and endovascular repair of abdominal aortic an-
eurysms. N Engl J Med 2004;351:1607e18.
3 AbuRahma AF, Campbell J, Stone PA, Nanjundappa A, Jain A,
Dean LS, et al. The correlation of aortic neck length to early and
late outcomes in endovascular aneurysm repair patients. J Vasc
Surg 2009;50:738e48.
4 Katsargyris A, Verhoeven EL. Endovascular strategies for
infrarenal aneurysms with short necks. J Cardiovasc Surg
(Torino) 2013;54:21e6.
5 Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal
graft implantation for abdominal aortic aneurysms. Ann Vasc
Surg 1991;5:491e9.
6 Volodos NL, Karpovich IP, Troyan VI, Kalashnikova Yu V,
Shekhanin VE, Ternyuk NE, et al. Clinical experience of the use
European Journal of Vascular and Endovascular Surgery Volume 48 Issue 2 p. 131e137 August/2014 137of self-ﬁxing synthetic prostheses for remote endoprosthetics
of the thoracic and the abdominal aorta and iliac arteries
through the femoral artery and as intraoperative endopros-
thesis for aorta reconstruction. Vasa 1991;33:93e5.
7 Fillinger M. Three-dimensional analysis of enlarging aneurysms
after endovascular abdominal aortic aneurysm repair in theGore
Excluder Pivotal clinical trial. J Vasc Surg 2006;43:888e95.
8 Haider SE, Najjar SF, Cho JS, Rhee RY, Eskandari MK,
Matsumura JS, et al. Sac behavior after aneurysm treatment
with the Gore Excluder low-permeability aortic endoprosthesis:
12-month comparison to the original Excluder device. J Vasc
Surg 2006;44:694e700.
9 Hogg ME, Morasch MD, Park T, Flannery WD, Makaroun MS,
Cho JS. Long-term sac behavior after endovascular abdominal
aortic aneurysm repair with the Excluder low-permeability
endoprosthesis. J Vasc Surg 2011;53:1178e83.
10 Bos WT, Tielliu IF, Van Den Dungen JJ, Zeebregts CJ,
Sondakh AO, Prins TR, et al. Results of endovascular abdominal
aortic aneurysm repair with selective use of the Gore Excluder.
J Cardiovasc Surg (Torino) 2009;50:159e64.
11 Lee CJKM, Morasch MD. Gore excluder device with the C3
delivery system for management of abdominal aortic aneu-
rysm. Open Access Surg 2012;5:15e21.
12 Chaikof EL, Brewster DC, Dalman RL, Makaroun MS, Illig KA,
Sicard GA, et al. The care of patients with an abdominal aortic
aneurysm: the Society for Vascular Surgery practice guidelines.
J Vasc Surg 2009;50:2e49.
13 Verhoeven EL, Oikonomou K, Mohner B, Renner H, Ritter W.
First experience with the new repositionable C3 excluder stent-
graft. J Cardiovasc Surg (Torino) 2011;52:637e42.
14 Bachoo P, Verhoeven EL, Larzon T. Early outcome of endovas-
cular aneurysm repair in challenging aortic neck morphology
based on experience from the GREAT C3 registry. J Cardiovasc
Surg (Torino) 2013;54:573e80.15 Katsargyris A, Botos B, Oikonomou K, Pedraza de Leistl M,
Ritter W, Verhoeven EL. The new C3 Gore Excluder stent-graft:
single-center experience with 100 patients. Eur J Vasc Endo-
vasc Surg 2014;47:342e8.
16 Grol R, Grimshaw J. From best evidence to best practice:
effective implementation of change in patients’ care. Lancet
2003;362:1225e30.
17 Biebl M, Hakaim AG, Lau LL, Oldenburg WA, Klocker J,
Neuhauser B, et al. Use of proximal aortic cuffs as an adjunc-
tive procedure during endovascular aortic aneurysm repair.
Vascular 2005;13:16e22.
18 Aburahma AF, Campbell JE, Mousa AY, Hass SM, Stone PA,
Jain A, et al. Clinical outcomes for hostile versus favorable
aortic neck anatomy in endovascular aortic aneurysm repair
using modular devices. J Vasc Surg 2011;54:13e21.
19 Katsargyris A, Oikonomou K, Bracale UM, Verhoeven EL. Un-
expected complication with the new C3 Excluder: cause and
treatment. Cardiovasc Intervent Radiol 2013;36:536e9.
20 Maleux G, Claes H, Van Holsbeeck A, Janssen R, Laenen A,
Heye S, et al. Ten years of experience with the Gore Excluder
stent-graft for the treatment of aortic and iliac aneurysms:
outcomes from a single center study. Cardiovasc Intervent
Radiol 2012;35:498e507.
21 Stokmans RA, Teijink JA, Forbes TL, Bockler D, Peeters PJ,
Riambau V, et al. Early results from the ENGAGE registry: real-
world performance of the Endurant Stent Graft for endovas-
cular AAA repair in 1262 patients. Eur J Vasc Endovasc Surg
2012;44:369e75.
22 Bos WT, Tielliu IF, Sondakh AO, Vourliotakis G, Bracale UM,
Verhoeven EL. Hybrid endograft solution for complex iliac
anatomy: Zenith body and Excluder limbs. Vascular 2010;18:
136e40.
